Stamatia Karagianni

Stamatia Karagianni

Auto-generated profile, based on publicly available information

Stamatia Karagianni

Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
LFLarissa Fischer
Larissa Fischer
DPDana M Parker
Dana M Parker
SMSamira Maboudian
Samira Maboudian
CFCorrina Fonseca
Corrina Fonseca
CTClaudia Tato-Fernández
Claudia Tato-Fernández
MSMichael Schöll
Michael Schöll
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.

9 January 2026 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
JBJulia R. Bacci
Julia R. Bacci
SKStamatia Karagianni
Stamatia Karagianni
ZAZampeta-Sofia Alexopoulou
Zampeta-Sofia Alexopoulou
SMShirine Moukaled
Shirine Moukaled
CTClaudia Tato-Fernández
Claudia Tato-Fernández
RPR W. Paterson
R W. Paterson
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous